These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30575740)

  • 1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.
    Zabaleta N; Barberia M; Martin-Higueras C; Zapata-Linares N; Betancor I; Rodriguez S; Martinez-Turrillas R; Torella L; Vales A; Olagüe C; Vilas-Zornoza A; Castro-Labrador L; Lara-Astiaso D; Prosper F; Salido E; Gonzalez-Aseguinolaza G; Rodriguez-Madoz JR
    Nat Commun; 2018 Dec; 9(1):5454. PubMed ID: 30575740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology.
    Estève J; Blouin JM; Lalanne M; Azzi-Martin L; Dubus P; Bidet A; Harambat J; Llanas B; Moranvillier I; Bedel A; Moreau-Gaudry F; Richard E
    Biochem Biophys Res Commun; 2019 Oct; 517(4):677-683. PubMed ID: 31402115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
    Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J
    J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a Primary Hyperoxaluria Type 1 Disease Model Via CRISPR/Cas9 System in Rats.
    Zheng R; Fang X; He L; Shao Y; Guo N; Wang L; Liu M; Li D; Geng H
    Curr Mol Med; 2018; 18(7):436-447. PubMed ID: 30539697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9-mediated knock-out of AGXT1 in HepG2 cells as a new in vitro model of Primary Hyperoxaluria Type 1.
    Gatticchi L; Grottelli S; Ambrosini G; Pampalone G; Gualtieri O; Dando I; Bellezza I; Cellini B
    Biochimie; 2022 Nov; 202():110-122. PubMed ID: 35964771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: CRISPR/Cas9-Mediated Glycolate Oxidase Disruption is an Efficacious and Safe Treatment for Primary Hyperoxaluria Type I.
    Assimos DG
    J Urol; 2019 May; 201(5):853-854. PubMed ID: 31009976
    [No Abstract]   [Full Text] [Related]  

  • 7. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I.
    Martin-Higueras C; Luis-Lima S; Salido E
    Mol Ther; 2016 Apr; 24(4):719-25. PubMed ID: 26689264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.
    Dutta C; Avitahl-Curtis N; Pursell N; Larsson Cohen M; Holmes B; Diwanji R; Zhou W; Apponi L; Koser M; Ying B; Chen D; Shui X; Saxena U; Cyr WA; Shah A; Nazef N; Wang W; Abrams M; Dudek H; Salido E; Brown BD; Lai C
    Mol Ther; 2016 Apr; 24(4):770-8. PubMed ID: 26758691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-mediated metabolic pathway reprogramming in a novel humanized rat model ameliorates primary hyperoxaluria type 1.
    Zheng R; Li Y; Wang L; Fang X; Zhang J; He L; Yang L; Li D; Geng H
    Kidney Int; 2020 Oct; 98(4):947-957. PubMed ID: 32464217
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Martinez-Turrillas R; Martin-Mallo A; Rodriguez-Diaz S; Zapata-Linares N; Rodriguez-Marquez P; San Martin-Uriz P; Vilas-Zornoza A; Calleja-Cervantes ME; Salido E; Prosper F; Rodriguez-Madoz JR
    Mol Ther Methods Clin Dev; 2022 Jun; 25():137-146. PubMed ID: 35402636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
    Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD
    Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New therapeutics for primary hyperoxaluria type 1.
    Dejban P; Lieske JC
    Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):344-350. PubMed ID: 35266883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.
    Li X; Knight J; Fargue S; Buchalski B; Guan Z; Inscho EW; Liebow A; Fitzgerald K; Querbes W; Todd Lowther W; Holmes RP
    Biochim Biophys Acta; 2016 Feb; 1862(2):233-9. PubMed ID: 26655602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1.
    Torella L; Klermund J; Bilbao-Arribas M; Tamayo I; Andrieux G; Chmielewski KO; Vales A; Olagüe C; Moreno-Luqui D; Raimondi I; Abad A; Torrens-Baile J; Salido E; Huarte M; Hernaez M; Boerries M; Cathomen T; Zabaleta N; Gonzalez-Aseguinolaza G
    EMBO Mol Med; 2024 Jan; 16(1):112-131. PubMed ID: 38182795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.
    Buchalski B; Wood KD; Challa A; Fargue S; Holmes RP; Lowther WT; Knight J
    Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165633. PubMed ID: 31821850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplex gene editing reduces oxalate production in primary hyperoxaluria type 1.
    Zheng R; Zhang DX; Shao YJ; Fang XL; Yang L; Huo YN; Li DL; Geng HQ
    Zool Res; 2023 Nov; 44(6):993-1002. PubMed ID: 37759334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1.
    Zheng R; Fang X; Chen X; Huang Y; Xu G; He L; Li Y; Niu X; Yang L; Wang L; Li D; Geng H
    Clin Transl Med; 2020 Dec; 10(8):e261. PubMed ID: 33377632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of primary hyperoxaluria: clues to innovative treatments.
    Dindo M; Conter C; Oppici E; Ceccarelli V; Marinucci L; Cellini B
    Urolithiasis; 2019 Feb; 47(1):67-78. PubMed ID: 30430197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer.
    Salido E; Rodriguez-Pena M; Santana A; Beattie SG; Petry H; Torres A
    Mol Ther; 2011 May; 19(5):870-5. PubMed ID: 21119625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy.
    Zhang X; Wang L; Liu M; Li D
    Sci China Life Sci; 2017 May; 60(5):468-475. PubMed ID: 28534255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.